Altimmune (NASDAQ:ALT) Given New $12.00 Price Target at HC Wainwright

Altimmune (NASDAQ:ALT) had its price target reduced by HC Wainwright from $15.00 to $12.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock.

ALT has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a neutral rating and a $13.00 price target for the company. B. Riley reiterated a buy rating and set a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th.

Altimmune Trading Down 0.7 %

Shares of NASDAQ:ALT opened at $9.29 on Monday. The company has a market capitalization of $499.15 million, a PE ratio of -5.63 and a beta of 0.05. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84. The firm has a 50 day simple moving average of $9.91 and a 200-day simple moving average of $6.94.

Institutional Trading of Altimmune

Several hedge funds have recently made changes to their positions in ALT. BlackRock Inc. increased its holdings in shares of Altimmune by 162.9% in the 2nd quarter. BlackRock Inc. now owns 3,664,274 shares of the company’s stock valued at $12,935,000 after purchasing an additional 2,270,219 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Altimmune by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 3,571,972 shares of the company’s stock valued at $40,185,000 after purchasing an additional 227,677 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Altimmune by 5.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,458,949 shares of the company’s stock valued at $12,210,000 after purchasing an additional 190,888 shares in the last quarter. State Street Corp increased its holdings in shares of Altimmune by 2,407.5% in the 3rd quarter. State Street Corp now owns 3,398,856 shares of the company’s stock valued at $43,403,000 after purchasing an additional 3,263,310 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Altimmune by 28.9% in the 2nd quarter. Marshall Wace LLP now owns 2,059,290 shares of the company’s stock valued at $7,269,000 after purchasing an additional 462,160 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.